| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Departments of Pathology*
and
Pharmacology,
Boyer Center for Molecular
Medicine, Yale University School of Medicine, New Haven, Connecticut;
and ISIS Pharmaceuticals,
Carlsbad, California
The protective genes that mediate endothelial cell (EC)
survival during angiogenesis have not been completely characterized.
Here, we show that an antisense oligonucleotide to the
apoptosis inhibitor survivin suppressed de novo
expression of survivin in ECs by vascular endothelial cell growth
factor (VEGF). In contrast, the survivin antisense
oligonucleotide did not affect anti-apoptotic bcl-2 levels in
endothelium. When assessed in cell death assays, antisense
targeting of survivin abolished the anti-apoptotic function of VEGF
against tumor necrosis factor-
- or ceramide-induced cell
death, enhanced caspase-3 activity, promoted the
generation of a 
17-kd active caspase-3 subunit, and
increased cleavage of the caspase substrate, polyADP ribose
polymerase. In contrast, the survivin antisense oligonucleotide
had no effect on EC viability in the absence of VEGF. Antisense
oligonucleotides to platelet-endothelial cell adhesion molecule-1
(PECAM-1, CD31), lymphocyte function-associated
molecule-3 (LFA-3, CD58), or intercellular adhesion
molecule-1 (ICAM-1, CD54) did not reduce the anti-apoptotic
function of VEGF in endothelium. When tested on other angiogenic
activities mediated by VEGF, survivin antisense treatment
induced rapid regression of three-dimensional vascular capillary
networks, but did not affect EC migration/chemotaxis. These
data suggest that the anti-apoptotic properties of VEGF during
angiogenesis are primarily mediated by the induced expression of
survivin in ECs. Manipulation of this pathway may increase EC viability
in compensatory angiogenesis or facilitate EC apoptosis and promote
vascular regression during tumor angiogenesis.
This article has been cited by other articles:
 |
|
 |
|
  T. Satoh, I. Okamoto, M. Miyazaki, R. Morinaga, A. Tsuya, Y. Hasegawa, M. Terashima, S. Ueda, M. Fukuoka, Y. Ariyoshi, et al. Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors Clin. Cancer Res., June 1, 2009; 15(11): 3872 - 3880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Mita, M. M. Mita, S. T. Nawrocki, and F. J. Giles Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics Clin. Cancer Res., August 15, 2008; 14(16): 5000 - 5005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Dudar, L. D. D'Andrea, R. Di Stasi, C. Pedone, and J. L. Wallace A vascular endothelial growth factor mimetic accelerates gastric ulcer healing in an iNOS-dependent manner Am J Physiol Gastrointest Liver Physiol, August 1, 2008; 295(2): G374 - G381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Virrey, S. Guan, W. Li, A. H. Schonthal, T. C. Chen, and F. M. Hofman Increased Survivin Expression Confers Chemoresistance to Tumor-Associated Endothelial Cells Am. J. Pathol., August 1, 2008; 173(2): 575 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Leung, Y. Xu, B. Mularski, H. Liu, S. Gurbuxani, and J. D. Crispino Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells J. Exp. Med., July 9, 2007; 204(7): 1603 - 1611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pennati, M. Folini, and N. Zaffaroni Targeting survivin in cancer therapy: fulfilled promises and open questions Carcinogenesis, June 1, 2007; 28(6): 1133 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, T. S. Park, and J. M. Gidday Hypoxic preconditioning protects human brain endothelium from ischemic apoptosis by Akt-dependent survivin activation Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2573 - H2581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Zwerts, F. Lupu, A. De Vriese, S. Pollefeyt, L. Moons, R. A. Altura, Y. Jiang, P. H. Maxwell, P. Hill, H. Oh, et al. Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure Blood, June 1, 2007; 109(11): 4742 - 4752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. P. Blanc-Brude, E. Teissier, Y. Castier, G. Leseche, A.-P. Bijnens, M. Daemen, B. Staels, Z. Mallat, and A. Tedgui IAP Survivin Regulates Atherosclerotic Macrophage Survival Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 901 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Caldas, J. R. Fangusaro, D. R. Boue, M. P. Holloway, and R. A. Altura Dissecting the role of endothelial SURVIVIN {Delta}Ex3 in angiogenesis Blood, February 15, 2007; 109(4): 1479 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McCarty and K. I. Block Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy Integr Cancer Ther, September 1, 2006; 5(3): 252 - 268. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Fukuda and L. M. Pelus Survivin, a cancer target with an emerging role in normal adult tissues Mol. Cancer Ther., May 1, 2006; 5(5): 1087 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Altieri Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol. Cancer Ther., March 1, 2006; 5(3): 478 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Huang, J. Li, L. Song, D. Zhang, Q. Tong, M. Ding, L. Bowman, R. Aziz, and G. D. Stoner Black Raspberry Extracts Inhibit Benzo(a)Pyrene Diol-Epoxide-Induced Activator Protein 1 Activation and VEGF Transcription by Targeting the Phosphotidylinositol 3-Kinase/Akt Pathway Cancer Res., January 1, 2006; 66(1): 581 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Wang, X. X. Sui, H. F. Simosa, M. K. Jain, D. C. Altieri, and M. S. Conte Regulation of Vein Graft Hyperplasia by Survivin, an Inhibitor of Apoptosis Protein Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2081 - 2087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Limaye, X. Li, C. Hahn, P. Xia, M. C. Berndt, M. A. Vadas, and J. R. Gamble Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members Blood, April 15, 2005; 105(8): 3169 - 3177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Xiang, N. Mizutani, Y. Luo, C. Chiodoni, H. Zhou, M. Mizutani, Y. Ba, J. C. Becker, and R. A. Reisfeld A DNA Vaccine Targeting Survivin Combines Apoptosis with Suppression of Angiogenesis in Lung Tumor Eradication Cancer Res., January 15, 2005; 65(2): 553 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn Vascular Endothelial Growth Factor and Angiogenesis Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Johnson and E. W. Howerth Survivin: A Bifunctional Inhibitor of Apoptosis Protein Vet. Pathol., November 1, 2004; 41(6): 599 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Blazquez, L. Gonzalez-Feria, L. Alvarez, A. Haro, M. L. Casanova, and M. Guzman Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas Cancer Res., August 15, 2004; 64(16): 5617 - 5623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lu, Y. Mu, C. Cao, F. Zeng, S. Schneider, J. Tan, J. Price, J. Chen, M. Freeman, and D. E. Hallahan Survivin As a Therapeutic Target for Radiation Sensitization in Lung Cancer Cancer Res., April 15, 2004; 64(8): 2840 - 2845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Spagnuolo, M. Corada, F. Orsenigo, L. Zanetta, U. Deuschle, P. Sandy, C. Schneider, C. J. Drake, F. Breviario, and E. Dejana Gas1 is induced by VE-cadherin and vascular endothelial growth factor and inhibits endothelial cell apoptosis Blood, April 15, 2004; 103(8): 3005 - 3012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Pisarev, B. Yu, R. Salup, S. Sherman, D. C. Altieri, and D. I. Gabrilovich Full-Length Dominant-Negative Survivin for Cancer Immunotherapy Clin. Cancer Res., December 15, 2003; 9(17): 6523 - 6533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fornaro, J. Plescia, S. Chheang, G. Tallini, Y.-M. Zhu, M. King, D. C. Altieri, and L. R. Languino Fibronectin Protects Prostate Cancer Cells from Tumor Necrosis Factor-{alpha}-induced Apoptosis via the AKT/Survivin Pathway J. Biol. Chem., December 12, 2003; 278(50): 50402 - 50411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Tu, X. H. Jiang, M. C. M. Lin, J. T. Cui, Y. Yang, C. T. Lum, B. Zou, Y. B. Zhu, S. H. Jiang, W. M. Wong, et al. Suppression of Survivin Expression Inhibits in Vivo Tumorigenicity and Angiogenesis in Gastric Cancer Cancer Res., November 15, 2003; 63(22): 7724 - 7732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Conway, F. Zwerts, V. Van Eygen, A. DeVriese, N. Nagai, W. Luo, and D. Collen Survivin-Dependent Angiogenesis in Ischemic Brain: Molecular Mechanisms of Hypoxia-Induced Up-Regulation Am. J. Pathol., September 1, 2003; 163(3): 935 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Donohue, C. M. Richards, S. A.N. Brown, H. N. Hanscom, J. Buschman, S. Thangada, T. Hla, M. S. Williams, and J. A. Winkles TWEAK Is an Endothelial Cell Growth and Chemotactic Factor That Also Potentiates FGF-2 and VEGF-A Mitogenic Activity Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 594 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Scappaticci Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies J. Clin. Oncol., September 15, 2002; 20(18): 3906 - 3927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Chavakis and S. Dimmeler Regulation of Endothelial Cell Survival and Apoptosis During Angiogenesis Arterioscler. Thromb. Vasc. Biol., June 1, 2002; 22(6): 887 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Armstrong, B. Bjorkblom, K. D. Hankenson, A. W. Siadak, C. E. Stiles, and P. Bornstein Thrombospondin 2 Inhibits Microvascular Endothelial Cell Proliferation by a Caspase-independent Mechanism Mol. Biol. Cell, June 1, 2002; 13(6): 1893 - 1905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tran, Z. Master, J. L. Yu, J. Rak, D. J. Dumont, and R. S. Kerbel A role for survivin in chemoresistance of endothelial cells mediated by VEGF PNAS, April 2, 2002; 99(7): 4349 - 4354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tran, Z. Master, J. L. Yu, J. Rak, D. J. Dumont, and R. S. Kerbel A role for survivin in chemoresistance of endothelial cells mediated by VEGF PNAS, April 2, 2002; 99(7): 4349 - 4354. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
